Mechanism of Action
SURGX uses patented XBIO Technology to attack biofilm structures, breaking the strong metallic bonds that hold the EPS together. This exposes the bacteria within the biofilm and makes them more vulnerable to attack and eradication. Bacteria that are enveloped within the biofilm disruption technology then experience cell lysis through a high osmolarity imbalance across the bacterial cell membrane and wall. XBIO Technology’s broad-spectrum efficacy helps defend from biofilm reformation.
Studies show SURGX provides broad-spectrum efficacy and multi-log microorganism reduction.
SURGX demonstrates up to 5-day efficacy in preventing MRSA bacterial growth.
Clinical and Scientific Evidence
Stevenson, P. Myntti, M. (2020). SurgX® in the role of SSSI prevention: Clinical Observations Supporting the Integration of Antibiofilm Strategy into Surgical Incision Management. Jacksonville, FL: Next Science.
Kim D, Namen W, Moore J, Buchanan M, Hayes V, Myntti M, Hakaim
A. Clinical Assessment of a Biofilm-disrupting Agent for the Management of Chronic Wounds Compared With Standard of Care: A Therapeutic Approach. Wounds. Epub 2018.
Miller KG, Tran PL, Haley CL, et al. Next science wound gel technology, a novel agent that inhibits biofilm development by gram-positive and gram-negative wound pathogens. Antimicrob Agents Chemother. 2014;58(6):3060–3072.
*It is not recommended to be used with silver dressing as SURGX will deactivate the silver, however, the combination does not pose a risk to the patient.
All trademarks and registered trademarks are the property of their respective owners.